But what if you want to incentivize investment in bold new drugs instead of me-too drugs? What if you want to encourage research into new areas that tangibly improve people's health? Then maybe, like India, you would only grant patents when that higher standard is met.
The realities of pharmaceutical research are brutal, consisting of decade-and-a-half long timescales, mind-numbing costs and exceedingly long, soul-crushing odds of success. In the fight against cancer, this rings especially true.